[144] Stoke Therapeutics, Inc. SEC Filing
Stoke Therapeutics filed a Form 144 indicating that a person affiliated with the company intends to sell 13,712 common shares, with an aggregate market value of $185,523.36, on or about 08/13/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing states there are 54,797,418 shares outstanding.
The shares to be sold were acquired from the issuer as equity awards: 9,264 restricted stock units on 03/15/2025 and 4,448 performance stock units on 12/03/2024. The filing reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information, with reference to Rule 10b5-1 language.
Stoke Therapeutics ha presentato un Form 144, indicando che una persona collegata alla societ脿 intende vendere 13,712 azioni ordinarie, per un valore di mercato complessivo di $185,523.36, intorno al 13/08/2025 tramite Morgan Stanley Smith Barney LLC sul NASDAQ. La segnalazione riporta 54,797,418 azioni in circolazione.
Le azioni da vendere sono state ottenute dall'emittente come premi azionari: 9,264 restricted stock units il 15/03/2025 e 4,448 performance stock units il 03/12/2024. Il deposito segnala "Nothing to Report" per titoli venduti negli ultimi tre mesi e include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali non divulgate, con riferimento alla Rule 10b5-1.
Stoke Therapeutics present贸 un Form 144 indicando que una persona vinculada a la compa帽铆a tiene la intenci贸n de vender 13,712 acciones ordinarias, por un valor de mercado total de $185,523.36, alrededor del 13/08/2025 a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ. La presentaci贸n se帽ala que hay 54,797,418 acciones en circulaci贸n.
Las acciones a vender fueron recibidas del emisor como compensaci贸n en acciones: 9,264 unidades de acciones restringidas el 15/03/2025 y 4,448 unidades de acciones por desempe帽o el 03/12/2024. La presentaci贸n informa "Nothing to Report" respecto a valores vendidos en los 煤ltimos tres meses e incluye la declaraci贸n habitual de que el vendedor no conoce informaci贸n material no divulgada, con referencia a la Rule 10b5-1.
Stoke Therapeutics電� Form 144毳� 鞝滌稖頃橃棳 須岇偓鞕� 甏�霠悳 鞚胳偓臧� 13,712 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜臧� $185,523.36鞐� 雼晿瓿� 攴� 鞁滌爯鞚� 2025雲� 8鞗� 13鞚�瓴届溂搿� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 瓯半灅霅� 鞓堨爼鞚措澕瓿� 氚濏様鞀惦媹雼�. 鞝滌稖靹滌棎 霌膘灛霅� 氚滍枆欤检嫕 靾橂姅 54,797,418欤检瀰雼堧嫟.
毵る弰 雽�靸� 欤检嫕鞚� 氚滍枆靷攵�韯� 欤检嫕 氤挫儊鞙茧 旆摑頃� 瓴冹溂搿�, 2025雲� 3鞗� 15鞚�鞐� 旆摑頃� 9,264臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(Restricted Stock Units)鞕� 2024雲� 12鞗� 3鞚�鞐� 旆摑頃� 4,448臧滌潣 靹标臣 旮半皹 欤检嫕 雼渼(Performance Stock Units)鞛呺媹雼�. 鞝滌稖靹滌棎電� 斓滉芳 3臧滌洈 雮� 毵る弰頃� 歃濌秾鞐� 甏�頃� "Nothing to Report"霛缄碃 旮办灛霅橃柎 鞛堨溂氅�, 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧 攵堧Μ 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃橂姅 響滌鞝� 歆勳垹( Rule 10b5-1 甏�霠� 氍戈惮)鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Stoke Therapeutics a d茅pos茅 un Form 144 indiquant qu'une personne li茅e 脿 la soci茅t茅 a l'intention de vendre 13,712 actions ordinaires, pour une valeur marchande totale de $185,523.36, aux alentours du 13/08/2025 via Morgan Stanley Smith Barney LLC sur le NASDAQ. Le d茅p么t pr茅cise qu'il y a 54,797,418 actions en circulation.
Les actions 脿 vendre ont 茅t茅 re莽ues de l'茅metteur au titre de r茅mun茅ration en actions : 9,264 unit茅s d'actions restreintes le 15/03/2025 et 4,448 unit茅s d'actions de performance le 03/12/2024. Le document signale "Nothing to Report" pour les titres vendus au cours des trois derniers mois et inclut la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable significative non divulgu茅e, en r茅f茅rence 脿 la Rule 10b5-1.
Stoke Therapeutics hat ein Formular 144 eingereicht, aus dem hervorgeht, dass eine mit dem Unternehmen verbundene Person plant, 13,712 Stammaktien mit einem Gesamtmarktwert von $185,523.36 am oder um den 13.08.2025 眉产别谤 Morgan Stanley Smith Barney LLC an der NASDAQ zu verkaufen. In der Meldung werden 54,797,418 ausstehende Aktien angegeben.
Die zu ver盲u脽ernden Aktien wurden vom Emittenten als Aktienverg眉tung erworben: 9,264 Restricted Stock Units am 15.03.2025 und 4,448 Performance Stock Units am 03.12.2024. Die Einreichung vermerkt "Nothing to Report" f眉r in den letzten drei Monaten verkaufte Wertpapiere und enth盲lt die 眉bliche Erkl盲rung, dass der Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen kenne, unter Bezugnahme auf die Rule 10b5-1.
- Regulatory disclosure filed providing broker, share count, aggregate value, and planned sale date
- Acquisition details disclosed: 9,264 RSUs (03/15/2025) and 4,448 PSUs (12/03/2024), improving transparency
- Insider plans to sell 13,712 shares, which investors may view as insider selling (aggregate value $185,523.36)
- No 10b5-1 plan adoption date shown in the visible filing text, so reliance on a prearranged plan is not clearly documented here
Insights
TL;DR: Routine Form 144 filing for a small-scale insider sale; unlikely to move market materially.
The Form 144 discloses a planned sale of 13,712 common shares with aggregate value $185,523.36, executed through Morgan Stanley on NASDAQ. Given the size relative to the stated 54,797,418 outstanding shares and the shares being recently issued as RSUs and PSUs, this appears to be a routine award monetization rather than a large disposition. The filing also shows no reportable sales in the prior three months.
TL;DR: Disclosure follows Rule 144 procedures; filing notes standard representation on material information and references Rule 10b5-1.
The notice identifies the broker and provides acquisition details for the securities (dates and award types), which supports transparency and regulatory compliance. The remarks include the customary attestation that the seller is unaware of undisclosed material adverse information. The filing does not list any prior sales in the last three months and does not show a plan adoption date in the visible text, so it is not possible from this document alone to confirm reliance on a dated 10b5-1 plan.
Stoke Therapeutics ha presentato un Form 144, indicando che una persona collegata alla societ脿 intende vendere 13,712 azioni ordinarie, per un valore di mercato complessivo di $185,523.36, intorno al 13/08/2025 tramite Morgan Stanley Smith Barney LLC sul NASDAQ. La segnalazione riporta 54,797,418 azioni in circolazione.
Le azioni da vendere sono state ottenute dall'emittente come premi azionari: 9,264 restricted stock units il 15/03/2025 e 4,448 performance stock units il 03/12/2024. Il deposito segnala "Nothing to Report" per titoli venduti negli ultimi tre mesi e include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali non divulgate, con riferimento alla Rule 10b5-1.
Stoke Therapeutics present贸 un Form 144 indicando que una persona vinculada a la compa帽铆a tiene la intenci贸n de vender 13,712 acciones ordinarias, por un valor de mercado total de $185,523.36, alrededor del 13/08/2025 a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ. La presentaci贸n se帽ala que hay 54,797,418 acciones en circulaci贸n.
Las acciones a vender fueron recibidas del emisor como compensaci贸n en acciones: 9,264 unidades de acciones restringidas el 15/03/2025 y 4,448 unidades de acciones por desempe帽o el 03/12/2024. La presentaci贸n informa "Nothing to Report" respecto a valores vendidos en los 煤ltimos tres meses e incluye la declaraci贸n habitual de que el vendedor no conoce informaci贸n material no divulgada, con referencia a la Rule 10b5-1.
Stoke Therapeutics電� Form 144毳� 鞝滌稖頃橃棳 須岇偓鞕� 甏�霠悳 鞚胳偓臧� 13,712 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜臧� $185,523.36鞐� 雼晿瓿� 攴� 鞁滌爯鞚� 2025雲� 8鞗� 13鞚�瓴届溂搿� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 瓯半灅霅� 鞓堨爼鞚措澕瓿� 氚濏様鞀惦媹雼�. 鞝滌稖靹滌棎 霌膘灛霅� 氚滍枆欤检嫕 靾橂姅 54,797,418欤检瀰雼堧嫟.
毵る弰 雽�靸� 欤检嫕鞚� 氚滍枆靷攵�韯� 欤检嫕 氤挫儊鞙茧 旆摑頃� 瓴冹溂搿�, 2025雲� 3鞗� 15鞚�鞐� 旆摑頃� 9,264臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(Restricted Stock Units)鞕� 2024雲� 12鞗� 3鞚�鞐� 旆摑頃� 4,448臧滌潣 靹标臣 旮半皹 欤检嫕 雼渼(Performance Stock Units)鞛呺媹雼�. 鞝滌稖靹滌棎電� 斓滉芳 3臧滌洈 雮� 毵る弰頃� 歃濌秾鞐� 甏�頃� "Nothing to Report"霛缄碃 旮办灛霅橃柎 鞛堨溂氅�, 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧 攵堧Μ 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃橂姅 響滌鞝� 歆勳垹( Rule 10b5-1 甏�霠� 氍戈惮)鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Stoke Therapeutics a d茅pos茅 un Form 144 indiquant qu'une personne li茅e 脿 la soci茅t茅 a l'intention de vendre 13,712 actions ordinaires, pour une valeur marchande totale de $185,523.36, aux alentours du 13/08/2025 via Morgan Stanley Smith Barney LLC sur le NASDAQ. Le d茅p么t pr茅cise qu'il y a 54,797,418 actions en circulation.
Les actions 脿 vendre ont 茅t茅 re莽ues de l'茅metteur au titre de r茅mun茅ration en actions : 9,264 unit茅s d'actions restreintes le 15/03/2025 et 4,448 unit茅s d'actions de performance le 03/12/2024. Le document signale "Nothing to Report" pour les titres vendus au cours des trois derniers mois et inclut la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable significative non divulgu茅e, en r茅f茅rence 脿 la Rule 10b5-1.
Stoke Therapeutics hat ein Formular 144 eingereicht, aus dem hervorgeht, dass eine mit dem Unternehmen verbundene Person plant, 13,712 Stammaktien mit einem Gesamtmarktwert von $185,523.36 am oder um den 13.08.2025 眉产别谤 Morgan Stanley Smith Barney LLC an der NASDAQ zu verkaufen. In der Meldung werden 54,797,418 ausstehende Aktien angegeben.
Die zu ver盲u脽ernden Aktien wurden vom Emittenten als Aktienverg眉tung erworben: 9,264 Restricted Stock Units am 15.03.2025 und 4,448 Performance Stock Units am 03.12.2024. Die Einreichung vermerkt "Nothing to Report" f眉r in den letzten drei Monaten verkaufte Wertpapiere und enth盲lt die 眉bliche Erkl盲rung, dass der Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen kenne, unter Bezugnahme auf die Rule 10b5-1.
FAQ
What does the Form 144 filed for STOK disclose?
How many STOK shares are planned to be sold and what is their value?
When and how were the shares being sold acquired?
Which broker will execute the sale for STOK?
Did the filer report any STOK securities sold in the past three months?
